A Study of APL-10456-Vaccine

Summary

AP09CP01 is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study which is conducted in Australia. The main purpose of this research study is to evaluate the safety, side effects, and immune response of APL-10456-Vaccine, a Rhinovirus (RV) Vaccine, when compared with a placebo in Younger and Older Healthy Volunteers

Timeline

Start

2026-02-16

Primary completion

2027-05-18

Completion

2027-05-18

Drugs

Indications